Success Metrics

Clinical Success Rate
83.3%

Based on 55 completed trials

Completion Rate
83%(55/66)
Active Trials
17(16%)
Results Posted
40%(22 trials)
Terminated
11(10%)

Phase Distribution

Ph phase_2
33
31%
Ph not_applicable
25
23%
Ph phase_1
13
12%
Ph phase_3
25
23%
Ph phase_4
11
10%

Phase Distribution

13

Early Stage

33

Mid Stage

36

Late Stage

Phase Distribution107 total trials
Phase 1Safety & dosage
13(12.1%)
Phase 2Efficacy & side effects
33(30.8%)
Phase 3Large-scale testing
25(23.4%)
Phase 4Post-market surveillance
11(10.3%)
N/ANon-phased studies
25(23.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

55 of 66 finished

Non-Completion Rate

16.7%

11 ended early

Currently Active

17

trials recruiting

Total Trials

107

all time

Status Distribution
Active(30)
Completed(55)
Terminated(11)
Other(11)

Detailed Status

Completed55
Not yet recruiting13
Recruiting12
Terminated11
unknown10
Active, not recruiting5

Development Timeline

Analytics

Development Status

Total Trials
107
Active
17
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 113 (12.1%)
Phase 233 (30.8%)
Phase 325 (23.4%)
Phase 411 (10.3%)
N/A25 (23.4%)

Trials by Status

completed5551%
unknown109%
not_yet_recruiting1312%
recruiting1211%
terminated1110%
suspended11%
active_not_recruiting55%

Recent Activity

Clinical Trials (107)

Showing 20 of 107 trialsScroll for more
NCT07742553Phase 2

Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

Not Yet Recruiting
NCT06396065Phase 3

Phase III Study of AK112 for NSCLC Patients

Active Not Recruiting
NCT06376981Phase 3

Hyaluronic Acid in Shoulder Tendinopathy

Recruiting
NCT07558642Not Applicable

Effects of Stellate Ganglion Block on Delirium and Circadian Rhythm in Geriatric Intensive Care Patients

Not Yet Recruiting
NCT07465263Phase 3

A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Recruiting
NCT02675374Phase 3

Hemodynamic Instability Prevented With Polaramine® Infusion Before Extracorporeal Circulation

Terminated
NCT06839664Phase 3

A Study of HS-20094 in Chinese Adults With Overweight or Obesity

Completed
NCT07603713Phase 2

Efficacy and Safety of LP-005 Injection in Patients With Moderate-to-Severe Periodontitis

Not Yet Recruiting
NCT07240922Phase 4

The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study

Active Not Recruiting
NCT00437762Phase 3

Effectiveness of Botulinum Toxin Injection in the Tennis Elbow Treatment

Completed
NCT06319534Not Applicable

Stellate Ganglion Block in Bulbar Palsy

Completed
NCT03604406Phase 2

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

Completed
NCT07415655Phase 2

Modulation of Cerebral Ischemia by Albumin

Recruiting
NCT06655454Phase 2

Supplemental Postoperative Bupivacaine Following Non-Surgical Endodontic Treatment

Recruiting
NCT05634876Phase 1

UB-312 in Patients With Synucleinopathies

Completed
NCT05184712Phase 3

Phase 3 Clinical Study of AK112 for NSCLC Patients

Active Not Recruiting
NCT07309614Phase 3

A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma

Recruiting
NCT05939245Not Applicable

Comparison of Plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) Level in De-resuscitation With Furosemide Group and Control Group

Completed
NCT03818035Phase 3

A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis

Completed
NCT07353749Phase 4

Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
107